NXTC – Nextcure Inc
NextCure, Inc.NXTC
$5.13Name : NextCure, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $13,728,445.00
EPSttm : -25.97
NextCure, Inc.
$5.13
0.77%$0.04Float Short %
4.14
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
7.22
EPS Last/This Y
8.29
EPS This/Next Y
3.51
Price
5.12
Target Price
17.5
Analyst Recom
1.67
Performance Q
-14
Relative Volume
0.19
Beta
1.27
Ticker: NXTC
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | NXTC | 6.23 | N/A | N/A | 0 |
| 2025-07-28 | NXTC | 5.54 | N/A | N/A | 0 |
| 2025-07-29 | NXTC | 5.27 | N/A | N/A | 0 |
| 2025-07-30 | NXTC | 5.01 | N/A | N/A | 0 |
| 2025-07-31 | NXTC | 4.9267 | N/A | N/A | 0 |
| 2025-08-01 | NXTC | 5.08 | N/A | N/A | 0 |
| 2025-08-04 | NXTC | 5.175 | N/A | N/A | 0 |
| 2025-08-05 | NXTC | 5.23 | N/A | N/A | 0 |
| 2025-08-06 | NXTC | 5.16 | N/A | N/A | 0 |
| 2025-08-07 | NXTC | 5 | N/A | N/A | 0 |
| 2025-08-08 | NXTC | 4.92 | N/A | N/A | 0 |
| 2025-08-11 | NXTC | 4.77 | N/A | N/A | 0 |
| 2025-08-12 | NXTC | 4.8 | N/A | N/A | 0 |
| 2025-08-13 | NXTC | 5.2 | N/A | N/A | 0 |
| 2025-08-14 | NXTC | 5.08 | N/A | N/A | 0 |
| 2025-08-15 | NXTC | 5.115 | N/A | N/A | 0 |
| 2025-08-18 | NXTC | 5.37 | N/A | N/A | 0 |
| 2025-08-19 | NXTC | 5.15 | N/A | N/A | 0 |
| 2025-08-20 | NXTC | 5.13 | N/A | N/A | 0 |
| 2025-08-21 | NXTC | 5.17 | N/A | N/A | 0 |
| 2025-08-22 | NXTC | 5.12 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | NXTC | 6.17 | 30.0 | - | -18.31 |
| 2025-07-28 | NXTC | 5.54 | 30.1 | - | -18.31 |
| 2025-07-29 | NXTC | 5.24 | 30.1 | - | -18.31 |
| 2025-07-30 | NXTC | 5.01 | 30.1 | - | -18.31 |
| 2025-07-31 | NXTC | 4.96 | 30.1 | - | -18.31 |
| 2025-08-01 | NXTC | 4.89 | 30.1 | - | -18.31 |
| 2025-08-04 | NXTC | 5.04 | 30.1 | - | -18.31 |
| 2025-08-05 | NXTC | 5.20 | 30.1 | - | -18.31 |
| 2025-08-06 | NXTC | 5.08 | 30.1 | - | -18.31 |
| 2025-08-07 | NXTC | 5.09 | 30.1 | - | -18.31 |
| 2025-08-08 | NXTC | 4.87 | 30.1 | - | -18.31 |
| 2025-08-11 | NXTC | 4.81 | 30.1 | - | -18.31 |
| 2025-08-12 | NXTC | 4.80 | 25.8 | - | -18.31 |
| 2025-08-13 | NXTC | 5.19 | 25.8 | - | -18.31 |
| 2025-08-14 | NXTC | 5.09 | 25.8 | - | -18.31 |
| 2025-08-15 | NXTC | 5.06 | 25.8 | - | -15.59 |
| 2025-08-18 | NXTC | 5.27 | 19.0 | - | -15.59 |
| 2025-08-19 | NXTC | 5.09 | 19.0 | - | -15.59 |
| 2025-08-20 | NXTC | 5.01 | 19.0 | - | -15.59 |
| 2025-08-21 | NXTC | 5.17 | 19.0 | - | -15.59 |
| 2025-08-22 | NXTC | 5.12 | 19.0 | - | -15.59 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | NXTC | 0.00 | 0 | 1.36 |
| 2025-07-28 | NXTC | 0.00 | 0 | 1.36 |
| 2025-07-29 | NXTC | 0.00 | 0 | 1.36 |
| 2025-07-30 | NXTC | 0.00 | 0 | 1.36 |
| 2025-07-31 | NXTC | 0.00 | 0 | 1.36 |
| 2025-08-01 | NXTC | 0.00 | 0 | 1.36 |
| 2025-08-04 | NXTC | 0.00 | 0 | 1.36 |
| 2025-08-05 | NXTC | 0.00 | 0 | 1.36 |
| 2025-08-06 | NXTC | 0.00 | 0 | 1.36 |
| 2025-08-07 | NXTC | 0.00 | 0 | 1.36 |
| 2025-08-08 | NXTC | 0.00 | 0 | 1.36 |
| 2025-08-11 | NXTC | 0.00 | 0 | 1.36 |
| 2025-08-12 | NXTC | 0.00 | 0 | 4.30 |
| 2025-08-13 | NXTC | 0.00 | 0 | 4.30 |
| 2025-08-14 | NXTC | 0 | 0 | 0 |
| 2025-08-15 | NXTC | 0 | 0 | 0 |
| 2025-08-18 | NXTC | 0 | -33.18 | 4.14 |
| 2025-08-19 | NXTC | 0.00 | -33.18 | 4.14 |
| 2025-08-20 | NXTC | 0.00 | -33.18 | 4.14 |
| 2025-08-21 | NXTC | 0.00 | -33.18 | 4.14 |
| 2025-08-22 | NXTC | 0.00 | -33.18 | 4.14 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-11.29
Avg. EPS Est. Current Quarter
-3.98
Avg. EPS Est. Next Quarter
-4.07
Insider Transactions
Institutional Transactions
-33.18
Beta
1.27
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
3
Growth Score
19
Sentiment Score
31
Actual DrawDown %
97
Max Drawdown 5-Year %
-98.1
Target Price
17.5
P/E
Forward P/E
PEG
P/S
P/B
0.38
P/Free Cash Flow
EPS
-25.91
Average EPS Est. Cur. Y
-15.59
EPS Next Y. (Est.)
-12.08
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.19
Return on Equity vs Sector %
-217.2
Return on Equity vs Industry %
-204.3
EPS 1 7Days Diff
2.7
EPS 1 30Days Diff
2.73
EBIT Estimation
NextCure, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 43
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading